Get started
Live feed
·
PRReleasevia Quantisnow
SELLAS Life Sciences Group Inc. logo

SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight
Quantisnow market dataNASDAQ
SELLAS Life Sciences Group Inc. logo
SLS
SELLAS Life Sciences Group Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Follow SLSFull SLS profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SLS (SELLAS Life Sciences Group Inc.) and more on Quantisnow.